Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen

• Main Authors: Fabio Selis, Giuseppina Focà, Annamaria Sandomenico, Carla Marra, Concetta Di Mauro, Gloria Saccani Jotti, Silvia Scaramuzza, Annalisa Politano, Riccardo Sanna, Menotti Ruvo, Giancarlo Tonon
• Format: Article
• Language: English
• Published: MDPI AG 2016-04-01
• Series: International Journal of Molecular Sciences
• Subjects: PEGylation; antibody fragment; Fab; papain digestion; pepsin digestion; pharmacokinetics
• Online Access: http://www.mdpi.com/1422-0067/17/4/491

PEGylation of biomolecules is a major approach to increase blood stream half-life, stability and solubility of biotherapeutics and to reduce their immunogenicity, aggregation potential and unspecific interactions with other proteins and tissues. Antibodies have generally long half-lives due to high molecular mass and stability toward proteases, however their size lowers to some extent their potential because of a reduced ability to penetrate tissues, especially those of tumor origin. Fab or otherwise engineered smaller fragments are an alternative but are less stable and are much less well retained in circulation. We have here investigated the effects of various PEGylations on the binding properties and in vivo half-life of Fab fragments derived from the enzymatic splitting of Trastuzumab. We find that PEGylation increases the half-life of the molecules but also strongly affects the ability to recognize the target antigen in a way that is dependent on the extent and position of the chemical modification. Data thus support the concept that polyethylene glycol (PEG) conjugation on Trastuzumab Fabs increases half-life but reduces their affinity and this is a fine balance, which must be carefully considered for the design of strategies based on the use of antibody fragments.